Glenmark Pharmaceuticals Ltd (GLENMARK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Glenmark Pharmaceuticals Ltd (GLENMARK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile


  • Products Id :- GDPH29625D
  • |
  • Pages: 65
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Glenmark Pharmaceuticals Ltd (Glenmark) is a pharmaceutical company which focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company's formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies. The company markets its products in North America, South America, Asia-Pacific and Africa. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd (GLENMARK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Private Equity 14

Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 14

Partnerships 16

Glenmark Pharma Enters into Agreement with Sam Chun Dang Pharm 16

Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 17

Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 19

Licensing Agreements 20

Glenmark Pharma Europe Enters into Licensing Agreement with Undisclosed Company 20

Harbour BioMed Enters into Licensing Agreement with Glenmark Pharma 21

Seqirus Enters into Licensing Agreement with Glenmark Specialty 22

Elite Pharma Enters into Licensing Agreement with Glenmark Pharma 23

Glenmark Pharma Enters into Licensing Agreement with Elite Pharma 24

Glenmark Pharma Enters into Licensing Agreement with Helsinn 25

Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 26

Glenmark Pharma Enters into Licensing Agreement with Cyndea Pharma 27

Glenmark Pharma Enters into Licensing Agreement with Advanced Proteome Therapeutics 28

Glenmark Pharma Enters into Licensing Agreement with Evestra for NuvaRing 29

Glenmark Pharma Enters into Licensing Agreement with Particle Sciences 30

Glenmark Generics Enters Into Licensing Agreement With Celon Pharma 31

Equity Offering 32

Glenmark Pharma Raises USD151 Million in Private Placement of Shares 32

Glenmark Pharma Plans to Raise USD300 Million in Private Placement 33

Debt Offering 34

Glenmark Pharma Prices Private Placement of 4.5% Bonds for USD200 Million 34

Glenmark Pharma to Raise up to USD200 Million in Public Offering of Bonds 35

Asset Transactions 36

Glenmark Pharma to Divest its Orthopaedic Business to True North 36

Acquisition 37

Glenmark Pharma Acquires Zorg Labs 37

Glenmark Pharmaceuticals Ltd-Key Competitors 38

Glenmark Pharmaceuticals Ltd-Key Employees 39

Glenmark Pharmaceuticals Ltd-Locations And Subsidiaries 40

Head Office 40

Other Locations & Subsidiaries 40

Recent Developments 43

Financial Announcements 43

May 29, 2018: Glenmark's consolidated revenue at Rs. 22,798.16 Mn. for Q4 FY 2017-18 43

Feb 09, 2018: Glenmark's consolidated revenue at Rs. 22,036.62 Mn for Q3 FY 2017-18 45

Nov 02, 2017: Glenmark's consolidated revenue increases by 1.46% to Rs. 22,565.90 Mn for Q2 FY 2017-18 46

Jul 27, 2017: Glenmark's consolidated revenue increases by 19.99% to Rs. 23,630.02 Mn for Q1 FY 2017-18 47

May 11, 2017: Glenmark's consolidated revenue increased by 6.52% to Rs. 24,571.83 Mn for Q4 FY 2016-17 48

Feb 02, 2017: Glenmark Pharmaceuticals Announces Quarter Results Ended December 31, 2016 50

Corporate Communications 51

Nov 02, 2017: Glenmark Appoints Mr. V. S. Mani as Predent & Global Chief Financial Officer 51

Mar 31, 2017: Glenmark: Change in designation of Director 52

Legal and Regulatory 53

Jul 17, 2018: Glenmark Pharmaceuticals to file appeal before NCLAT against CCI penalties 53

Jul 13, 2018: CCI penalises Glenmark Pharma, other entities for unfair business practices 54

Nov 28, 2017: Glenmark Pharmaceuticals: USFDA Audit -Baddi Unit 55

Mar 15, 2017: Glenmark's Receives US FDA Approval For Ankleshwar plant 56

Feb 21, 2017: Glenmark Pharmaceuticals Provides Update On Ankleshwar Plant In Gujarat 57

Product News 58

12/27/2017: Glenmark Pharmaceuticals receives ANDA approval for Norethindrone Acetate and Ethinyl Estradiol Tablets USP and Ferrous Fumarate Tablets, 1 mg/20 mcg 58

10/23/2017: Glenmark Pharmaceuticals Presenting New Data from Respiratory Portfolio at the ACAAI Annual Scientific Meeting 2017 59

Apr 23, 2018: Glenmark clinical trial in Jaipur dragged into controversy, CDSCO to probe allegations 60

Product Approvals 61

Apr 25, 2017: Glenmark Pharmaceuticals Initiates Clinical Investigation for GBR 310, its Proposed Biosimilar Candidate for XOLAIR 61

Clinical Trials 62

Dec 13, 2017: Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris in Patients with Perennial Allergic Rhinitis 62

Mar 29, 2017: Glenmark Pharmaceuticals Reports Positive Results from a Phase 3 Trial of GSP 301, Mometasone/Olopatadine Fixed-Dose Combination Nasal Spray, in Seasonal Allergic Rhinitis 63

Mar 08, 2017: Glenmark Pharmaceuticals Receives FDA Clearance of IND for GSP 304 64

Appendix 65

Methodology 65

About GlobalData 65

Contact Us 65

Disclaimer 65

List of Figures

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

List of Tables

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Glenmark Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Glenmark Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 11

Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Glenmark Pharma May Sell Stake in Active Pharmaceutical Ingredient Business 14

Glenmark Pharma Enters into Agreement with Sam Chun Dang Pharm 16

Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 17

Glenmark Pharma Enters Into Co-Development Agreement With Forest Labs To Develop mPGES-1 Inhibitors 19

Glenmark Pharma Europe Enters into Licensing Agreement with Undisclosed Company 20

Harbour BioMed Enters into Licensing Agreement with Glenmark Pharma 21

Seqirus Enters into Licensing Agreement with Glenmark Specialty 22

Elite Pharma Enters into Licensing Agreement with Glenmark Pharma 23

Glenmark Pharma Enters into Licensing Agreement with Elite Pharma 24

Glenmark Pharma Enters into Licensing Agreement with Helsinn 25

Glenmark Pharma Enters into Licensing Agreement with Ligand Pharma 26

Glenmark Pharma Enters into Licensing Agreement with Cyndea Pharma 27

Glenmark Pharma Enters into Licensing Agreement with Advanced Proteome Therapeutics 28

Glenmark Pharma Enters into Licensing Agreement with Evestra for NuvaRing 29

Glenmark Pharma Enters into Licensing Agreement with Particle Sciences 30

Glenmark Generics Enters Into Licensing Agreement With Celon Pharma 31

Glenmark Pharma Raises USD151 Million in Private Placement of Shares 32

Glenmark Pharma Plans to Raise USD300 Million in Private Placement 33

Glenmark Pharma Prices Private Placement of 4.5% Bonds for USD200 Million 34

Glenmark Pharma to Raise up to USD200 Million in Public Offering of Bonds 35

Glenmark Pharma to Divest its Orthopaedic Business to True North 36

Glenmark Pharma Acquires Zorg Labs 37

Glenmark Pharmaceuticals Ltd, Key Competitors 38

Glenmark Pharmaceuticals Ltd, Key Employees 39

Glenmark Pharmaceuticals Ltd, Subsidiaries 40

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Glenmark Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license
Single User License
USD 250 INR 17815
Site License
USD 500 INR 35630
Corporate User License
USD 750 INR 53445

NEWSLETTER BY CATEGORY




Testimonials

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com